BioNTech posts revenues well ahead of expectations

10 August 2021

German biotech BioNTech (Nasdaq: BNTX) saw its shares close up 15% at $447.23 on Monday, after it provided an update on its corporate progress and reported financial results for the second quarter ended June 30, 2021.

Total revenues for the period were estimated to be 5,308.5 million euros ($6.24 billion), compared to 41.7 million euros for the three months ended June 30, 2020, and well exceeded consensus estimates of 3.3 billion euros. Revenues were driven by 4.1 billion euros gross profit sharing with partner Pfizer (NYSE: PFE) on their jointl- developed COVID-19 vaccine, Comirnaty/BNT162b2, as well as 1 billion euros from BioNTech’s direct sales in Germany and Turkey,

Net profit was 2,787.2 million euros for the three months ended June 30, 2021, compared to an 88.3 million-euros net loss for the like period of 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK